Ecnoglutide vs Lixisenatide

Ecnoglutide is an experimental GLP-1 receptor agonist still in development, with no FDA-approved treatments yet. Lixisenatide, sold under the brand names Adlyxin and Soliqua, is an approved GLP-1 receptor agonist used to treat type 2 diabetes. The main practical difference is that Lixisenatide is already on the market, while Ecnoglutide is still being studied.

AI summary of the sources below.